The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice

Dasatinib (Sprycel) is a tyrosine kinase inhibitor approved for treatment of chronic myeloid leukemia. In this study, we identify dasatinib as a potent inducer of Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α mRNA. Dasatinib increased PGC-1α mRNA expression up to 6-fold in 3T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Endocrinology
Egile Nagusiak: Sylow, Lykke, Long, Jonathan Z., Lokurkar, Isha A., Zeng, Xing, Richter, Erik A., Spiegelman, Bruce M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Endocrine Society 2016
Gaiak:
Special Series: Endocrine Society Centennial Celebration
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5086530/
https://ncbi.nlm.nih.gov/pubmed/27589085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2016-1398
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak